In the near future, the administration of immune checkpoint inhibitors, including the blockade of the PD-1/PD-L1 pathway, will probably be an effective therapeutic approach for the treatment of thymic epithelial tumors. This evidence concerns the gene PDCD1 and thymic epithelial neoplasm.